^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Prolymphocytic Leukemia |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
T-Cell Prolymphocytic Leukemia...FIRST-LINE THERAPY...FMC (fludarabine, mitoxantrone, cyclophosphamide) followed by alemtuzumab (IV) in selected patients
